You are here » Home » Companies » Company Overview » Zenotech Laboratories Ltd

Zenotech Laboratories Ltd.

BSE: 532039 Sector: Health care
NSE: N.A. ISIN Code: INE486F01012
BSE 11:36 | 29 Nov 42.90 0
(0.00%)
OPEN

43.80

HIGH

44.70

LOW

40.45

NSE 05:30 | 01 Jan Zenotech Laboratories Ltd
OPEN 43.80
PREVIOUS CLOSE 42.90
VOLUME 5163
52-Week high 62.65
52-Week low 26.20
P/E 46.13
Mkt Cap.(Rs cr) 262
Buy Price 42.35
Buy Qty 23.00
Sell Price 42.90
Sell Qty 544.00
OPEN 43.80
CLOSE 42.90
VOLUME 5163
52-Week high 62.65
52-Week low 26.20
P/E 46.13
Mkt Cap.(Rs cr) 262
Buy Price 42.35
Buy Qty 23.00
Sell Price 42.90
Sell Qty 544.00

Zenotech Laboratories Ltd. (ZENOTECHLAB) - Chairman Speech

Company chairman speech

ZENOTECH LABORATORIES LIMITED ANNUAL REPORT 2006-2007 CHAIRMAN'S REPORT Dear Shareholders Over the last four years, your company's research and development team has developed technology platforms in generic biologicals, monoclonal antibodies and speciality injeetables like oncology. As a result, your company has one of the most robust product pipelines in the speciality / generic biologics space. Your company has licensed its generic C - CSF to Ranbaxy for clinical development and launch in the EU and later in the US market. Your company is one of the very few companies that has a fully validated product and a EU/US FDA approvable biologics manufacturing facilities in India. Your company has several other such products that will be taken up for clinical development with partners in the very near future. In speciality drugs pipeline, your company has developed seven general injectables for ANDA submissions in the US in collaboration with Ranbaxy. These seven ANDAs are to be filed in this calendar year. Several other ANDAs in speciality/oncology area are being taken up for development in the coming year. Your company has come a long way since its biologics operations started four years back. We have robust product pipelines with strong future potential, US FDA approvable manufacturing facilities and a highly dedicated and motivated team to take the business forward. However, there comes a time when the business model can be fully operationalized only with the help of a strategic partner. Your Board of Directors have chosen Ranbaxy to be the strategic partner, who brings strong competencies in pre- clinical and clinical development, global regulatory expertise, strong intellectual property skills, global marketing reach and above all, a strong financial wherewithal. Over the past two years, both the organizations shared a wonderful working relationship with great chemistry between the teams. The decision to expand our engagement is a statement of our unified goal to make India a strong contender in the international biopharmaceuticals market. Best Wishes, Dr. Jayaram Chigurupati Chairman and Managing Director
.